Preventive use of lamivudine in postgastrectomy adenocarcinoma patients carrying HBV to prevent from severe liver damage and viral activation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002121

Enrollment

Unknown

Registered

2012-04-23

Start date

2012-04-23

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer and HBV

Interventions

1:lamivudine

2:Radiotherapy combined with Chemotherapy that contains oxaliplatin

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The pathological diagnosis of stomach cancer; 2. The laboratory diagnosis of hepatitis b carriers; 3. Hepatitis b virus is inactive (HBV DNA<1000/ml) and Liver function is normal before treatment; 4. Liver function is abnormal slightly and recover soon after treatment.

Exclusion criteria

Exclusion criteria: 1. Tumor metastasis to the liver; 2. liver dysfunction and Viral replication before treatment; 3. Radiation interrupt for reasons other than liver dysfunction and viral reactivation; 4. anti-viral therapy before treatment; 5. other reasons that cannot recept radiotherapy orchemotherapy.

Design outcomes

Primary

Measure	Time frame
Liver function;	—

Countries

China

Contacts

Public ContactXu Feng

xufeng_1100@yahoo.com.cn+86 18980601781

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026